High-dose docosahexaenoic acid supplements did reach the brain in older adults at risk for dementia - and it made no measurable difference to their memory. That is the finding of a randomised, double-blind, placebo-controlled trial published in eBioMedicine, which tracked participants over two years and included people carrying the APOE e4 variant, the strongest common genetic risk factor for late-onset Alzheimer's disease.
The trial was designed to answer a specific question that has dogged omega-3 research: whether the supplements actually get where they are supposed to go. Earlier disappointing results were often attributed to insufficient delivery, particularly in APOE e4 carriers, who are thought to handle DHA differently. On that narrow point, the supplement worked. Brain DHA levels rose. But cognitive performance did not improve, and neither did measures of brain structure.
That combination - clear target engagement without clinical benefit - shifts the question from how much DHA reaches the brain to what the brain does with it once it arrives. DHA is built into nerve cell membranes, where it supports synaptic function and helps regulate neuroinflammation, and its levels tend to be lower in people with amyloid deposition, cognitive decline, and late-onset Alzheimer's. The trial suggests that simply restoring supply does not restore function, at least not over two years in this population.
For anyone hoping that fish oil at a high enough dose might slow cognitive decline, the result is a check on that expectation rather than a final verdict. It does, however, narrow the field for future work, pointing researchers toward how DHA is metabolised and used within brain tissue rather than toward ever-larger doses.